In primary esophageal carcinomas and cell lines, deletions and point mutations in CDKN2A gene have been reported in 16% to 82% of cases [22,31], and hypermethylation of promoter region in 20% to 88% of ESCC and precancerous lesions [30,32]. This evidence concerns the gene CDKN2A and esophageal squamous cell carcinoma.